- Brenig Therapeutics to Present AI-Enabled Design of a Brain-Penetrant NLRP3 Inhibitor at Keystone Symposia Neuroinflammation in Health and Disease
- Brenig Therapeutics to Present Hybrid AI Drug Discovery Platform at Keystone Symposia Computational Advances in Drug Discovery
- Brenig Therapeutics to Present Phase 1 Data for BT-267 at the American Academy of Neurology (AAN) 2026 Annual Meeting
- Brenig Therapeutics Announces Oral Presentation of Phase 1 Data for BT-267 at AD/PD™ 2026, and Provides Updates on BT-409, its NLRP3 Inhibitor Program
- Brenig Therapeutics Announces Initiation of First-in-Human Study of BT-409, a Brain-Selective NLRP3 Inhibitor, and Provides Update on BT-267, its LRRK2 Program
- Brenig Therapeutics Names Megan McGill as Chief Executive Officer
- Brenig Therapeutics Announces the Initiation of First-in-Human Clinical Trial of BT-267, a Best-in-Class LRRK2 Inhibitor for Parkinson’s Disease
- Brenig Therapeutics Announces $65 Million Series A Financing to Advance Leading Pre-Clinical Parkinson’s Disease Pipeline
- Brenig Therapeutics Presented New Data for the Best-in-Class LRRK2 Inhibitor Targeting Parkinson’s Disease at the ACS Spring 2024 Conference
- Brenig Therapeutics Unveils Superior Safety Profile of LRRK2 Inhibitor BT-0267 with Exceptional CSF/Plasma Ratio at Future of Parkinson’s Disease Conference
v4
